Mostrar de todas as regiões

Portugal

Brasil

Espanha

Europa

Estados Unidos e Canadá

América Latina

Oceania

FDA Approves Pembrolizumab for First-Line Treatment of Metastatic NSCLC

ESMO - European Society of Cancer Immunology and Immunotherapy

EMA Adopts a New Indication for Nivolumab

ESMO - European Society of Cancer Immunology and Immunotherapy

Personalised Cancer Vaccines

ESMO - European Society of Cancer Immunology and Immunotherapy

Acquired Resistance to PD-1 Blockade in Melanoma

ESMO - European Society of Cancer Immunology and Immunotherapy

In Search of Biomarkers in Onco-Immunology

ESMO - European Society of Cancer Immunology and Immunotherapy

NICE Issues Evidence Based Recommendations on Nivolumab for Previously Treated Advanced RCC

ESMO - European Society of Cancer Immunology and Immunotherapy

Evolving Field of CAR-T-Cell Therapy

ESMO - European Society of Cancer Immunology and Immunotherapy

EMA Recommends to Extend Indications for Pembrolizumab

ESMO - European Society of Cancer Immunology and Immunotherapy

CAR T-Cell Immunotherapy Induces Complete Remissions in Patients with Refractory DLBCL

ESMO - European Society of Cancer Immunology and Immunotherapy

FDA Approves Atezolizumab for Metastatic NSCLC

ESMO - European Society of Cancer Immunology and Immunotherapy

Durvalumab in Heavily Pretreated EGFR/ALK Wildtype Advanced NSCLC

ESMO - European Society of Cancer Immunology and Immunotherapy

Atezolizumab in Patients With Locally Advanced and Metastatic Urothelial Carcinoma

ESMO - European Society of Cancer Immunology and Immunotherapy

ESID 2020 - Call for Bids

ESID - European Society for Immunodeficiencies

FDA Approves Pembrolizumab for Patients with Recurrent or Metastatic HNSCC with Disease Progression on or After Platinum-Containing Chemotherapy

ESMO - European Society of Cancer Immunology and Immunotherapy

FDA Approves Nivolumab for SCCHN

ESMO - European Society of Cancer Immunology and Immunotherapy